240 related articles for article (PubMed ID: 7553634)
1. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Ring DB; Alpaugh RK
J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
[TBL] [Abstract][Full Text] [Related]
3. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
4. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
[TBL] [Abstract][Full Text] [Related]
7. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
9. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
10. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
Weiner LM; Holmes M; Richeson A; Godwin A; Adams GP; Hsieh-Ma ST; Ring DB; Alpaugh RK
J Immunol; 1993 Sep; 151(5):2877-86. PubMed ID: 8103070
[TBL] [Abstract][Full Text] [Related]
11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
12. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Deo Y; Graziano R; Fisher JL; Meyer L; Mrozek-Orlowski M
J Clin Oncol; 1995 Sep; 13(9):2281-92. PubMed ID: 7545221
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
14. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
[TBL] [Abstract][Full Text] [Related]
15. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with CD64-directed immunotherapy. An overview.
Curnow RT
Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Hartmann F; Renner C; Jung W; da Costa L; Tembrink S; Held G; Sek A; König J; Bauer S; Kloft M; Pfreundschuh M
Clin Cancer Res; 2001 Jul; 7(7):1873-81. PubMed ID: 11448899
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
